Evaluate the Efficacy and Safety of Rosuvastatin Versus Simvastatin in Type 2 Diabetic Patients With Dyslipidemia
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This is a phase IV, randomized, open-label, parallel-arm, comparative and forced- titration
study to compare the efficacy and safety of rosuvastatin versus simvastatin in patients with
type 2 DM and dyslipidemia. When comparing the efficacy of rosuvastatin 20 mg with
simvastatin 40 mg for the treatment of type 2 DM with dyslipidemia, rosuvastatin 20 mg is
superior to simvastatin 40 mg in achieving the combined goal of LDL-C (<100 mg/dL) and
non-HDL-C (<130 mg/dL).